Filters

Pp-146 manufacturers

Filters

1 products found

pp-146

Concentrate for solution for infusion

Dossier type
CTD
Dossier status
Under development
Country of origin
European Union
GMP approvals
EU GMP
Comments
Indication: 1L advanced cutaneous melanoma (PRAME+/HLA-A*02:01+) Clinical stage: Phase 3 Modality: Biologic (ImmTAC bispecific: soluble TCR against PRAME peptide/HLA-A*02:01 fused to anti-CD3 scFv) Mechanism / Target: Redirects polyclonal T cells to kill PRAME-presenting tumour cells; targets intracellular antigen presented on MHC-I — inaccessible to conventional mAbs Route / form: Intravenous infusion (weekly) Differentiation: Access to intracellular proteome (99%+ of tumour antigens); allele-specific targeting; ImmTAC proven class (tebentafusp approved for uveal melanoma 2022); 1L setting
Manufacturer #39177

Commercial-stage biopharmaceutical with approved ImmTAC bispecific for uveal melanoma. Pioneers TCR-based bispecific T-cell engagers targeting intracellular tumour antigens. Wholly owned Phase 3 cutaneous melanoma programme expanding the ImmTAC platform.
 

Want to see all products?

Subscribe today to benefit from:

  • Streamlined product sourcing - the leading CTD dossiers database focused on finished dosage formulations

  • Direct negotiations - connect and negotiate directly with manufacturers without any brokerage fee

  • Increased profitability - secure the best commercial terms for your business by comparing offers from several manufacturers

Request Subscription

Willing to unlock more features?

Please fill out form and send us your specific requirements, and we will get back to you as soon as possible

Want unlimited access to the Pipelinepharma database?

Become a subscriber to unlock:

  • Streamlined product sourcing: access the only CTD dossier pipeline and sourcing platform.

  • Direct connections: communicate directly with CTD dossier owners and manufacturers with no brokerage fees.

  • Higher profitability: compare multiple supplier offers and secure the best commercial terms.

  • Expanded network: view supplier portfolios and stay updated on new products.

  • Value-added product ideas: discover products with lower competition potential.

  • Access to marketing authorizations for sale: find already registered products in your target markets.